Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Absolute Bioavailability of Lanabecestat
NCT03222427Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2018
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of lanabecestat in Alzheimer's disease (AD) (2 arms), sponsored by AstraZeneca. Primary endpoint: Absolute Bioavailability of LY3314814 at Day 1. Started Jan 2018; status: completed.
02
Drugs
lanabecestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03222427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03222427.